Schering, Sanofi execs face questions

Sanofi Pasteur

While they were reporting their earnings, Schering-Plough and Sanofi-Aventis executives both found themselves on a hot seat. Schering CEO Fred Hassan (photo) faced questions about how he managed the controversial Enhance study--even hearing hints that he should depart, as one analyst called the trial "the worst PR disaster I think I ever recall." That's a big change for Hassan, who's been lauded for bringing Schering out of the ditch since he took over in 2003.

Meanwhile, Sanofi's R&D chief, Paul Chew, plus some FDA staffers, are expected to be grilled by the House Energy and Commerce Committee today in a hearing about the antibiotic Ketek, which was linked with liver failure last February. The committee wants to know whether the FDA knew about a Ketek study that included falsified data.

- read the Hassan article
 

Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.